Barclays
SRNE

Barclays’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Barclays’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,332,719
Closed -$2.07M – 5532
2022
Q4 		$2.07M Buy
2,332,719
+337,068
+17% +$447K ﹤0.01% 2243
2022
Q3 		$3.13M Buy
1,995,651
+1,829,031
+1,098% +$4.15M ﹤0.01% 1448
2022
Q2 		$335K Buy
166,620
+115,761
+228% +$200K ﹤0.01% 3121
2022
Q1 		$118K Sell
50,859
-327,570
-87% -$1.02M ﹤0.01% 3709
2021
Q4 		$1.76M Buy
378,429
+242,451
+178% +$1.51M ﹤0.01% 2466
2021
Q3 		$1.04M Buy
135,978
+93,676
+221% +$794K ﹤0.01% 2766
2021
Q2 		$410K Sell
42,302
-167,596
-80% -$1.33M ﹤0.01% 3186
2021
Q1 		$1.74M Sell
209,898
-121,206
-37% -$1.28M ﹤0.01% 2402
2020
Q4 		$2.26M Sell
331,104
-27,759
-8% -$223K ﹤0.01% 2141
2020
Q3 		$4M Sell
358,863
-25,413
-7% -$233K ﹤0.01% 1551
2020
Q2 		$2.41M Buy
384,276
+172,071
+81% +$659K ﹤0.01% 1939
2020
Q1 		$391K Buy
212,205
+520
+0.2% +$1.5K ﹤0.01% 3783
2019
Q4 		$716K Buy
211,685
+116,107
+121% +$277K ﹤0.01% 3971
2019
Q3 		$205K Buy
95,578
+20,162
+27% +$47K ﹤0.01% 4951
2019
Q2 		$201K Buy
75,416
+42,985
+133% +$155K ﹤0.01% 5105
2019
Q1 		$154K Sell
32,431
-71,241
-69% -$187K ﹤0.01% 5031
2018
Q4 		$249K Buy
103,672
+22,157
+27% +$72.4K ﹤0.01% 4434
2018
Q3 		$359K Buy
81,515
+44,436
+120% +$246K ﹤0.01% 4539
2018
Q2 		$267K Sell
37,079
-68,421
-65% -$465K ﹤0.01% 4484
2018
Q1 		$543K Sell
105,500
-4,644
-4% -$33K ﹤0.01% 3895
2017
Q4 		$419K Buy
110,144
+79,444
+259% +$207K ﹤0.01% 4034
2017
Q3 		$52K Buy
30,700
+3,700
+14% +$6.79K ﹤0.01% 5335
2017
Q2 		$54K Buy
27,000
+25,532
+1,739% +$49.8K ﹤0.01% 5317
2017
Q1 		$6K Buy
1,468
+822
+127% +$4.12K ﹤0.01% 6246
2016
Q4 		$3K Buy
+646
New +$3.88K ﹤0.01% 6287
2014
Q3 		– Sell
-1,000
Closed -$6K – 7876
2014
Q2 		$6K Buy
+1,000
New +$7.54K ﹤0.01% 7080

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Barclays's SRNE Position: Q1 2023 in Review

Barclays sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 2,332,719 shares — an estimated $2.07M sold.

Barclays first reported a position in SRNE in Q2 2014 and held it in 26 quarters. The position peaked at $4M in Q3 2020. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Barclays reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Barclays sold 2,332,719 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $2.07M.
  • Barclays first reported a position in Sorrento Therapeutics, Inc. in Q2 2014 and held it in 26 quarters.
  • Barclays's Sorrento Therapeutics, Inc. position peaked at $4M in Q3 2020.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.